Home Coffee product NeonMind announces the launch of functional mushroom coffees as a dietary supplement...

NeonMind announces the launch of functional mushroom coffees as a dietary supplement in the United States


Enter Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

VANCOUVER, BC / ACCESSWIRE / June 29, 2021 / NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company“), a psychedelic drug development company, is pleased to announce that it has launched its NeonMind branded functional mushroom coffee products as a dietary supplement in the United States. Initial launch includes two ground coffee references which are now available for delivery throughout the US Two SKUs of instant coffee are expected to be added within a month.

The new US sales website is live at intl.neonmind.com and is supported by Shopify. Products can be purchased individually and can be ordered as a subscription for a 10% discount. The website was designed to be mobile-friendly and to focus on a customer-centric strategy. Consumers can sign up for the NeonMind newsletter to receive the latest news, product releases and recipe information.

Each of the functional mushroom blends and selected herbs in NeonMind coffees contain adaptogens, which means they work with the body to help manage physical, mental and emotional stressors. Functional mushroom specifically refers to varieties of mushrooms that have a health benefit beyond nutrition. Functional mushrooms found in NeonMind coffees, such as cordyceps, lion’s mane, reishi, and turkey tail; provide long-term physical, neurological and immunological benefits.

The initial product launch will include two varieties of ground coffee. Protect Blend is a Peruvian coffee with medium roast French vanilla, turkey tail, cordyceps, Moringa extract and Amla extract. These ingredients have the proven benefit of relieving stress, supporting the immune system and supporting cognitive functions. Focus Blend is a dark roasted Peruvian coffee with lion’s mane extract, reishi extract, Gotu Kola extract and Brahmi extract. These ingredients are a healthy source of fungal polysaccharides with immunomodulatory properties that help improve memory and cognitive function, increase alertness, support the immune system, and combat mental and physical stress. The company will soon launch its two instant coffee blends in the United States as dietary supplements.

NeonMind Coffee Food Supplements follow all FDA regulations that focus on comprehensive GMP (Good Manufacturing Practices) to ensure the identity, purity, quality, strength and composition of dietary supplements. NeonMind only uses certified organic mushroom extracts that go through the decoction process (traditional boiling water) to maximize the bioavailability of the product. NeonMind follows strict US Pharmacopoeia guidelines for lead and other chemicals required by Proposition 65 for safe daily consumption. All final production batches are sent to a third party lab for rigorous microbial testing so that the copacker issues the certificate of analysis of the product which means the product is safe for the consumer market.

The global functional mushroom market was valued at USD 25.4 billion in 2020, and it is expected to register a compound annual growth rate of 8.44% during the forecast period 2021-2026, according to a report by Mordor Intelligence.

About NeonMind Biosciences Inc.

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to treat obesity and weight management issues and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in the development of drugs based on psychedelic compounds with two main candidate drugs based on psilocybin targeting obesity; (ii) a medical services division focused on launching specialized mental health clinics that integrate psychedelic therapies into traditional psychotherapy settings; and (iii) a consumer products division which currently sells mushroom infused products to promote health and wellness.

In its pharmaceutical division, NeonMind has two separate programs for the development of psilocybin-based drugs targeting obesity. NeonMind’s first drug candidate uses psilocybin as an agonist of the serotonin 5-HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate uses low-dose psilocybin as an agonist of the 5-HT2C receptor, which controls appetite.

NeonMind has created a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate innovative, evidence-based treatments to meet a variety of mental health needs.

NeonMind’s consumer division currently sells NeonMind branded coffee products in Canada through NeonMind’s direct-to-consumer e-commerce platform in Canada and the United States.

For more information on NeonMind, visit www.NeonMindBiosciences.com.

Rob Tessarolo, President and CEO, NeonMind Biosciences Inc.

[email protected]
Phone. : 416-750-3101

Investor Relations:

Edge communications
[email protected]
Phone. : 1-866-318-6874

KCSA strategic communication
Scott Eckstein / Tim Regan
[email protected]
Phone. : 212-896-1210

Media inquiries:

KCSA strategic communication
Annie graf
[email protected]
Phone. : 786-390-2644

The Canadian Securities Exchange has not reviewed, approved or disapproved of the contents of this press release.

Caution Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or the future performance of NeonMind. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters which are not facts historical records are intended to identify information and are based on NeonMind’s current belief or assumptions about the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel and its expectations regarding the development of its intellectual property and other stages of its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those envisaged by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. Statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE: NeonMind Biosciences Inc.

See the source version on accesswire.com:

Source link


Please enter your comment!
Please enter your name here